19096848

Source:http://linkedlifedata.com/resource/pubmed/id/19096848

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0024027, umls-concept:C0257291, umls-concept:C1999216, umls-concept:C2239176
pubmed:issue	3
pubmed:dateCreated	2009-6-8
pubmed:abstractText	Hepatocellular carcinoma (HCC) is characterized by hypervascularity and chemoresistance. Protein kinase C (PKC) participates in cancer progression by enhancing anti-apoptotic signals, angiogenesis, and chemoresistance. Statins have a selective anti-cancer effect due to over-expression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoAR) in cancer cells, but statins may also activate PKC. Thus, we hypothesized that simultaneous treatment with statin and PKC inhibitor might synergistically enhance their anti-tumor efficacies against HCCs.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7806519
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Hydroxymethylglutaryl-CoA..., http://linkedlifedata.com/resource/pubmed/chemical/Indoles, http://linkedlifedata.com/resource/pubmed/chemical/Lovastatin, http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase C, http://linkedlifedata.com/resource/pubmed/chemical/enzastaurin, http://linkedlifedata.com/resource/pubmed/chemical/protein kinase C beta
pubmed:status	MEDLINE
pubmed:month	Aug
pubmed:issn	1432-0843
pubmed:author	pubmed-author:BangYung-JueYJ, pubmed-author:JangIn-JinIJ, pubmed-author:KimJung-RyulJR, pubmed-author:KimWonW, pubmed-author:KimYoon-JunYJ, pubmed-author:LeeHyo-SukHS, pubmed-author:YoonJung-HwanJH
pubmed:issnType	Electronic
pubmed:volume	64
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	497-507
pubmed:meshHeading	pubmed-meshheading:19096848-Animals, pubmed-meshheading:19096848-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:19096848-Apoptosis, pubmed-meshheading:19096848-Carcinoma, Hepatocellular, pubmed-meshheading:19096848-Cell Line, Tumor, pubmed-meshheading:19096848-Disease Progression, pubmed-meshheading:19096848-Drug Synergism, pubmed-meshheading:19096848-Humans, pubmed-meshheading:19096848-Hydroxymethylglutaryl-CoA Reductase Inhibitors, pubmed-meshheading:19096848-In Situ Nick-End Labeling, pubmed-meshheading:19096848-Indoles, pubmed-meshheading:19096848-Liver Neoplasms, Experimental, pubmed-meshheading:19096848-Lovastatin, pubmed-meshheading:19096848-Male, pubmed-meshheading:19096848-Mice, pubmed-meshheading:19096848-Mice, Inbred C3H, pubmed-meshheading:19096848-Microvessels, pubmed-meshheading:19096848-Neoplasm Transplantation, pubmed-meshheading:19096848-Protein Kinase C
pubmed:year	2009
pubmed:articleTitle	Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma.
pubmed:affiliation	Department of Internal Medicine, Seoul National University Boramae Hospital, Seoul, South Korea.
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't